The COLCORONA study is for people newly diagnosed with COVID-19 who are not sick enough to need hospitalization. To be eligible, one must be age 40 or older with one additional risk factor (listed below).
Should a patient qualify and enroll, they will take 0.5 mg of colchicine or a placebo for 30 days. Of note, this medication is used to treat gout and FMF. The goal is to see whether this common anti-inflammatory medication can help decrease the progression of disease. Research suggests that early use of this drug may help dampen inflammation that the body produces in response to COVID and enable patients to recover without being hospitalized.
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 510 participants
Primary Purpose: Treatment
Official Title: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID)
Actual Study Start Date: April 2, 2020
Estimated Study Completion Date: July 2021
Risk Factors (at least 1 needed to qualify):
- 70 years or older
- Uncontrolled high blood pressure
- Known respiratory disease such as asthma or COPD
- known heart failure or coronary disease
- Fever of ≥38.4°C (101°F) within the last 48 hours
- Shortness of breath
Thank you for your interest in advancing COVID-19 research.
Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.
If you have any difficulties or questions, please contact our support specialists at [email protected]
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.